Medexus Pharmaceuticals Inc.MDP.TO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · medexus.com

Medexus Pharmaceuticals Inc. is a Toronto-based specialty pharmaceutical company with a fully integrated North American commercial infrastructure, focused on orphan drugs and rare diseases in the therapeutic areas of rheumatology, auto-immune disease, specialty oncology, allergy, and pediatric diseases. The company commercializes specialty drugs in both Canada and the United States through its Medexus Pharma Canada and Medexus Pharma USA divisions.

Key ratios

Operating cash flow growth

-28.0%TTM

2026 -21.5%2025 28.4%

EPS growth

-85.6%TTM

FCF / Sales

13.7%TTM

2026 18.8%2025 22.0%2024 16.5%2023 -1.4%

Net margin

-2.3%TTM

2026 -2.4%2025 2.1%2024 -0.2%2023 1.1%

ROA

3.0%TTM

2026 2.3%2025 4.6%2024 5.0%2023 3.5%

ROE

-4.7%TTM

2026 -4.7%2025 5.5%2024 -0.8%2023 6.1%

Revenue growth

-2.2%TTM

2026 -8.3%2025 -4.2%2024 4.6%

Recent news

Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date 2026-08-10 · Newsfile Medexus Schedules First Fiscal Quarter 2027 Conference Call 2026-07-30 · Newsfile Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection 2026-06-25 · Medexus Pharmaceuticals Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call 2026-06-16 · Medexus Pharmaceuticals Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada 2026-06-09 · Medexus Pharmaceuticals

Track MDP.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer